<DOC>
	<DOCNO>NCT02793960</DOCNO>
	<brief_summary>This single-center study investigate effect topical cream patient 12 year age old diagnose epidermolysis bullosa .</brief_summary>
	<brief_title>Topical BPM31510 3.0 % Cream Patients With Epidermolysis Bullosa</brief_title>
	<detailed_description>The trial conduct patient form Epidermolysis Bullosa ( EB ) least 1 active EB wind 2.5 50 cm2 size 10 % Body Surface Area . The investigator identify `` index lesion '' lesion treatment An area un-involved skin also treat study cream . This used test produce tiny blister th underlie tissue examine use special microscope . Patients apply study cream</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<criteria>1 . Male female least 12 year age time screen . 2 . Have primary , histologically confirm EB verify immunofluorescent antigenic mapping ( EM ) prior start application study drug 3 . Have dermatological disease may adversely impact wound heal . 4 . Willing refrain use topical cream lotion study drug designate area treatment period wash designate area next application do . 5 . Willing refrain exposure excessive direct sunlight ultraviolet light duration study . 6 . Laboratory value test list Study Schedule within local reference range define local laboratory , `` range '' test result clinically acceptable investigator . Acceptable `` range '' value generally within patient 's normal baseline level due concurrent medication disease process exception INR PT/APTT . 7 . Caregiver/guardian patient able follow study require instruction likely complete study visit requirement . 8 . Has provide write informed consent patient legal guardian , include consent tissue examine store Department Dermatology Cutaneous Surgery . If patient 12 17 year age , assent must give patient . 9 . Guardian provide write consent allow photograph target EB lesion ( ) use part study data documentation . 10 . Females childbearing potential must negative urine serum pregnancy test screen use acceptable form birth control ( oral/implant/injectable/transdermal contraceptive , intrauterine device , condom , diaphragm , abstinence , monogamous relationship partner vasectomy ) . 11 . Have INR value 0.81.2 well normal PT/APTT . 12 . With least 1 active EB wind 2.5 50 cm2 size nonflexual surface 1 . Received systemic therapy live skin equivalent graft past 30 day prior baseline visit . 2 . Known suspected systemic cancer lymphoma leukemia . 3 . Evidence dermatological disease confound skin condition treatment area , e.g. , BCC , actinic keratosis , rosacea , psoriasis , atopic dermatitis , eczema , xerodermapigmentosa , clinical evidence infection . 4 . Concurrent disease treatment suppress immune system . 5 . Any chronic medical condition , judgment investigator ( ) , interfere performance study would place patient undue risk . 6 . Known sensitivity ingredient trial medication ( BPM31510 3.0 % Cream 7 . Treatment systemic immunomodulators immunosuppressant within 2 month prior enrollment , duration longer 2 week . 8 . Use topical immunomodulators topical tacrolimus . 9 . Use systemic topical steroid within 30 day prior enrollment exclude ( inhaled steroid ophthalmic drop contain steroid allow ) . 10 . Any elective nonelective surgery biopsy EB , surgeries treatment sequela EB gtube placement esophageal dilatation within 4 week prior enrollment study . Elective procedure pertain skin graft allow time . 11 . Current enrollment investigational drug device study participation study within 4 week enrollment . 12 . In investigator 's opinion , evidence unwillingness inability patient caregiver follow restriction complete study . 13 . Has clot disorder , treat anticoagulant . 14 . Any abnormal laboratory value concurrent illness , opinion investigator , preclude patient 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>